Kolluri, Krishna KalyanAlifrangis, ConstantineKumar, NeelamIshii, YukiPrice, StaceyMichaut, MagaliWilliams, StevenBarthorpe, SydLightfoot, HowardBusacca, SaraSharkey, AnnabelYuan, ZhenqiangSage, Elizabeth KVallath, SabarinathLe Quesne, JohnTice, David AAlrifai, Doraidvon Karstedt, SylviaMontinaro, AntonellaGuppy, NaomiWaller, David ANakas, ApostolosGood, RobertHolmes, AlanWalczak, HenningFennell, Dean AGarnett, MathewIorio, FrancescoWessels, LodewykMcDermott, UltanJanes, Samuel M2019-06-192019-06-192018-01-18Kolluri, K K, Alifrangis, C, Kumar, N, Ishii, Y, Price, S, Michaut, M, Williams, S, Barthorpe, S, Lightfoot, H, Busacca, S, Sharkey, A, Yuan, Z, Sage, E K, Vallath, S, Le Quesne, J, Tice, D A, Alrifai, D, von Karstedt, S, Montinaro, A, Guppy, N, Waller, D A, Nakas, A, Good, R, Holmes, A, Walczak, H, Fennell, D A, Garnett, M, Iorio, F, Wessels, L, McDermott, U & Janes, S M 2018, 'Loss of functional BAP1 augments sensitivity to TRAIL in cancer cells', eLife, vol. 7, e30224. https://doi.org/10.7554/eLife.30224PubMedCentral: PMC5773178ORCID: /0000-0002-9009-421X/work/61759370http://hdl.handle.net/2164/12413Funding Wellcome (WT097452MA) Constantine Alifrangis Wellcome Trust (106555/Z/14/Z) Neelam Kumar Cancer Research UK (A17341) Henning Walczak Cancer Research UK Ultan McDermott Wellcome (WT107963AIA) Samuel M Janes The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.3139432engSDG 3 - Good Health and Well-beingAnimalsCell Line, TumorHumansLung Neoplasms/physiopathologyMesothelioma/physiopathologyMiceRepressor Proteins/metabolismTNF-Related Apoptosis-Inducing Ligand/metabolismTumor Suppressor Proteins/metabolismUbiquitin Thiolesterase/metabolismR MedicineWellcome TrustWT097452MA106555/Z/14/ZWT107963AIACancer Research UKA17341RJournal article10.7554/eLife.302247